Effects of Atypical Antipsychotics on Blood Cell Levels in Older Adults
Retrospective Study on the Hematological Effects of Atypical Antipsychotics (AAPs) in a Geriatric Population: What is the Role of 5-HT2 Receptors
This study looks at how certain antipsychotic medications affect blood cell levels in older adults to see if they cause any problems, especially with white blood cells.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06107322 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the hematological effects of atypical antipsychotics, particularly focusing on neutropenia, in an elderly population. It aims to understand the role of 5-HT2 receptors in the differentiation and mobilization of hematopoietic cells among older patients receiving these medications. The study population includes elderly individuals hospitalized in various geriatric care settings, where the use of clozapine and other atypical antipsychotics is common for treating behavioral disorders associated with dementia. By analyzing the occurrence of white blood cell abnormalities, the study seeks to improve prescribing practices for this vulnerable group.
Who should consider this trial
Good fit: Ideal candidates are elderly individuals aged 65 and older who are hospitalized in geriatric care settings and require treatment with atypical antipsychotics.
Not a fit: Patients who have pre-existing white blood cell abnormalities or those who have been on neuroleptics prior to admission may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to safer prescribing practices for atypical antipsychotics in elderly patients, reducing the risk of serious blood-related side effects.
How similar studies have performed: While there have been studies on clozapine in similar contexts, this specific investigation into the role of 5-HT2 receptors in the elderly population is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major subject (≥ 65 years old) * Subject hospitalized in Geriatric Internal Medicine, in Geriatric Follow-up Care and Rehabilitation, in a Long-Term Care Unit or Important Medical-Technical Care, in a Reinforced Accommodation Unit or in a Cognitive-Behavioral Unit at Strasbourg University Hospitals) * Subject not opposing the reuse of their data for the purposes of this research. * Indication for the introduction of the neuroleptic indicated * Available dosage and frequency of administration and duration of treatment Exclusion Criteria: * Subject having expressed opposition to participating in the study * Presence of a neuroleptic before admission to the University Hospitals of Strasbourg, excluding readmission of a patient included * Neuroleptics not present on the discharge prescription for long-term treatment * Neuroleptics prescribed for less than 48 hours * Presence of a white lineage anomaly prior to the initiation of neuroleptic treatment * Patient contraindicated for taking a long-term neuroleptic. * Hematological disease with white lineage abnormality (lymphoma, leukemia, myelodysplasia, mye syndrome
Where this trial is running
Strasbourg
- Service de Pharmacie - Stérilisation - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Estelle AYME-DIETRICH, Pharm, PhD
- Email: estelle.ayme@chru-strasbourg.fr
- Phone: 33 3 68 85 30 83
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.